Røsjø H, Dahl MB, Jørgensen M, Røysland R, Brynildsen J, Cataliotti A, Christensen G, Høiseth AD, Hagve TA, Omland T (2015) Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study
Clin Chem, 61 (8), 1087-97
PubMed 26056354 DOI 10.1373/clinchem.2015.239673
Holditch SJ, Schreiber CA, Nini R, Tonne JM, Peng KW, Geurts A, Jacob HJ, Burnett JC, Cataliotti A, Ikeda Y (2015) B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension
Hypertension, 66 (1), 199-210
PubMed 26063669 DOI 10.1161/HYPERTENSIONAHA.115.05610
Aspelin T, Eriksen M, Ilebekk A, Cataliotti A, Carlson CR, Lyberg T (2014) β-blockade abolishes the augmented cardiac tPA release induced by transactivation of heterodimerised bradykinin receptor-2 and β2-adrenergic receptor in vivo
Thromb Haemost, 112 (5), 951-9
PubMed 25078038 DOI 10.1160/TH14-01-0059
McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC (2014) M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
J Am Heart Assoc, 3 (1), e000206
PubMed 24385449 DOI 10.1161/JAHA.113.000206
Ichiki T, Izumi R, Cataliotti A, Larsen AM, Sandberg SM, Burnett JC (2013) Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis
Peptides, 48, 21-6
PubMed 23927843 DOI 10.1016/j.peptides.2013.07.020
Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC (2012) Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
J Am Coll Cardiol, 60 (22), 2305-12
PubMed 23122795 DOI 10.1016/j.jacc.2012.07.056
Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J, Cataliotti A (2012) Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP
J Am Coll Cardiol, 60 (16), 1558-65
PubMed 23058313 DOI 10.1016/j.jacc.2012.05.049
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC (2012) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
Eur Heart J, 34 (12), 886-893c
PubMed 22942338 DOI 10.1093/eurheartj/ehs262
Malatino LS, Cataliotti A, Stancanelli B, Zoccali C (2012) Hepatocyte growth factor and cardiomyopathy in dialysis patients
Hypertension, 60 (3), e24; author reply e25-6
PubMed 22868387 DOI 10.1161/HYPERTENSIONAHA.112.198424
Cataliotti A, Costello-Boerrigter LC, Chen HH, Textor SC, Burnett JC (2012) Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension
Mayo Clin Proc, 87 (4), 413-5
PubMed 22469356 DOI 10.1016/j.mayocp.2012.02.003